This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

StemCells, Inc. CEO Discusses Interim 6-Month Data From Spinal Cord Injury Trial - Call Transcript

Stocks in this article: STEM

Stephen Huhn, M.D., FACS, FAAP

This morning we have about 20 or 21 Slides to go through and as Martin said I’ll have some brief remarks in the first few slides and then I’m going to have Dr. Curt go through the interim data in more detail and then we’ll finish up with a Q&A at the end. The Phase I/II study design, just to remind everyone is an open label clinical investigation dealing with a single dose and a fixed dose of the human central nervous system stem cell which is delivered directly into the spinal cord at a dose of 20 million cells.

Patients are immuno suppressed because this is an alginate transplant for a period of nine months post operatively. The trial is designed to enroll 12 subjects who have a thoracic level injury from the second thoracic segment down to the 11 th segment. Patients are eligible to enroll in this trial who are between three and 12 months after injury and this corresponds to what we believe is generally considered the sub acute or late sub acute to early chronic phase of spinal cord injury.

In addition to the timeframe after injury patients who both have a complete and incomplete type of injury are eligible for the trial and will be enrolled in a sequential fashion. The first cohort of the trial, the subject of our discussion today, are those patients who have complete injury and by that I mean patients who have lost sensory function and motor function below the level of spinal cord trauma. This of course corresponds with what we call the AIS cohort A.

The trial will then continue after we dose this first cohort into patients with incomplete injury AISA B and ASIA C patients. With each cohort we have a data monitoring committee that will review the status of not only the recent safety data but the equivalent safety data from the prior dosed patients as we continue in the trial. The trial is first and foremost designed to examine safety, tolerability, and feasibility of our interventions but we’re also obviously expanding a lot of effort to determine whether we have any signals of an effectiveness.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs